Esperion Therapeutis.Inc. buy Bank of America Co.
Summary
This prediction is currently active. With a performance of 57.77% the BUY prediction by Bank_of_America_Co_ is a big success. This prediction currently runs until 15.06.24. The prediction end date can be changed by Bank_of_America_Co_ at any time. Bank_of_America_Co_ has 50% into this predictionEsperion Therapeutics, Inc. (NASDAQ: ESPR) is a biopharmaceutical company primarily focused on the development and commercialization of innovative lipid management therapies to address the unmet medical needs of patients with high cholesterol. With its flagship products, NEXLETOL® and NEXLIZET®, the company aims to provide alternative treatment options for individuals who cannot tolerate statins or require additional LDL-C lowering despite statin therapy. Esperion is driven by its commitment to improve cardiovascular health globally and maintains a steadfast dedication to researching and developing advanced cholesterol-lowering therapies.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Esperion Therapeutis.Inc. | -8.967% | -8.967% |
iShares Core DAX® | 1.662% | 4.835% |
iShares Nasdaq 100 | 0.667% | 0.000% |
iShares Nikkei 225® | -2.139% | -4.786% |
iShares S&P 500 | 0.564% | 0.775% |
Comments by Bank_of_America_Co_ for this prediction
In the thread Esperion Therapeutis.Inc. diskutieren